Page last updated: 2024-11-07

pilocarpine and Parkinson Disease, Secondary

pilocarpine has been researched along with Parkinson Disease, Secondary in 1 studies

Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
(+)-pilocarpine : The (+)-enantiomer of pilocarpine.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Collins-Praino, LE1
Paul, NE1
Ledgard, F1
Podurgiel, SJ1
Kovner, R1
Baqi, Y1
Müller, CE1
Senatus, PB1
Salamone, JD1

Other Studies

1 other study available for pilocarpine and Parkinson Disease, Secondary

ArticleYear
Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.
    The European journal of neuroscience, 2013, Volume: 38, Issue:1

    Topics: Adenosine A2 Receptor Antagonists; Animals; Deep Brain Stimulation; Disease Models, Animal; Dopamine

2013